正确认识类风湿关节炎炎性病变与关节损伤的“分离”现象
摘要
类风湿关节炎（RA）是一种以关节进行性炎性滑膜炎为特征的自身免疫病，可侵蚀关节软骨和软骨下骨。部分患者在发病的第一年即出现不可逆性关节损伤，2年后约70％的患者出现影像学破坏。甲氨蝶呤（MTX）是一种经典的改变病情的抗风湿药（DMARD），但对许多患者疗效欠佳或作用不持久，故常需与其他DMARD联合使用。既往一直认为，在RA的形成与发展中，关节炎症反应与关节损伤的进展是平行的，且关系非常密切，而TNF可能是参与这二个过程的关键性细胞因子。
出处
《中华内科杂志》
CAS
CSCD
北大核心
2008年第5期353-354,共2页
Chinese Journal of Internal Medicine
参考文献9
-
1Fuchs HA, Kaye J J, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol, 1989,16:585-591.
-
2Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody ) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase Ⅲ trial. ATTRACT Study Group. Lancet, 1999,354 : 1932-1939.
-
3Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab ( a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum ,2004,50 : 1400-1411.
-
4van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum,2006,54 : 1063-1074.
-
5BmedveldFC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A muhicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum, 2006,54 : 26-37.
-
6Kraan MC, Versendaal H, Jonker M, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum, 1998,41: 1481-1488.
-
7Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum, 2004,50:1051-1065.
-
8Breedveld FC, Emery P, Keystone E,et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis ,2004,63:149-155.
-
9Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum, 2006,54 : 702- 710.
-
1DMARD是什么?[J].现代医院,2009,9(2):143-143.
-
2杜凯阳,肖征宇.柳氮磺吡啶治疗类风湿关节炎研究进展[J].中国药物与临床,2008,8(6):480-482. 被引量：9
-
3戴欢.雷公藤多甙治疗风湿性关节炎25例临床观察[J].中国煤炭工业医学杂志,2001,4(8):628-628. 被引量：1
-
4刘靓婧,吴斌,李延萍,张莹.老年难治性类风湿关节炎的治疗研究进展[J].老年医学与保健,2015,21(6):448-451. 被引量：4
-
5董怡.生物制剂在风湿病中的应用进展[J].中华风湿病学杂志,2004,8(11):696-696. 被引量：1
-
6刘冬梅,薛红霞,杨丽丽,崔华东.小剂量糖皮质激素联合DMARD治疗类风湿关节炎的临床研究[J].实用药物与临床,2012,15(4):244-245. 被引量：10
-
7Kimme L Hyrich,李君(译).转变观念 类风湿关节炎疑似患者应及早转诊至风湿专科[J].英国医学杂志中文版,2008,11(3):183-184.
-
8生物制品治疗类风湿关节炎[J].国际生物制品学杂志,2010(3):143-143.
-
9卢添宝,张志智.生物制剂在类风湿关节炎治疗中的研究进展[J].现代医药卫生,2009,25(18):2818-2820.
-
10王宇,马晶,赵彦萍,梅轶芳,张志毅.长期应用小剂量激素对类风湿关节炎患者的临床疗效及安全性研究[J].现代生物医学进展,2014,14(32):6281-6283. 被引量：4
